BioTime Inc (BTX) - Medical Equipment - Deals and Alliances Profile
October 2018
71
About the Report
About the Report
Summary
BioTime Inc (BioTime) is a clinical-stage biotechnology company. It focuses on developing cures or treatments based on its core proprietary technology platforms for cell replacement and cell/drug delivery.The company's aesthetics products under development include Renevia , a potential treatment for facial lipoatrophy and facial aesthetics; Premvia for tendon and wound-management applications; OpRegen for the treatment of dry form of age-related macular degeneration (AMD); product for retinal restoration; HyStem for stroke recovery; ReGlyde for viscosupplementation and drug delivery; and bone grafting products. BioTime's products can be used in oncology, neuroscience, orthopedics and blood and vascular diseases. It also has interests in companies involved in offering therapeutic products in oncology and neurology, and biopsy tests for diagnosis of cancer. The company has operations in the US, Hong Kong, Israel and Singapore. BioTime is headquartered in California, the US.
BioTime Inc (BTX)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
BioTime Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
BioTime Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
BioTime Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
BioTime Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
BioTime Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
BioTime Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
BioTime Inc, Medical Equipment, Deal Details 12
Partnerships 12
OncoCyte Enters into Licensing Agreement with Cornell University for PanC-Dx 12
OncoCyte Enters into Co-Development Agreement with Abcodia for PanC-Dx Test 13
OncoCyte Expands Co-Development Agreement with Wistar Institute 14
Heraeus Medical Enters into Licensing Agreement with OrthoCyte 15
OncoCyte Enters into Licensing Agreement with Wistar Institute of Anatomy and Biology 16
Equity Offering 18
OncoCyte to Raise USD4 Million in Private Placement of Shares and Warrants 18
OncoCyte Raises USD10 Million in Private Placement of Shares 19
BioTime Completes Public Offering of Shares for USD28.8 Million 20
OncoCyte Plans to Raise up to USD50 Million in Public Offering of Securities 22
OncoCyte Raises USD5.7 Million in Private Placement of Shares upon Exercise of Warrants 23
Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 24
BioTime to Raise up to USD25 Million in Private Placement of Shares 26
OncoCyte Raises USD2 Million in Private Placement of Shares upon Exercise of Warrants 27
OncoCyte Raises USD3.2 Million in Private Placement of Units 28
OncoCyte Raises USD7.3 Million in Private Placement of Units 29
BioTime Raises USD5 Million in Private Placement of Shares 30
BioTime Raises USD20.4 Million in Private Placement of Shares 31
OncoCyte Raises USD3.3 Million in Private Placement of Shares 33
BioTime Completes Private Placement Of Shares For USD 6.4 Million 34
BioTime Announces Public Offering Of Shares For Up To USD 15 Million 35
BioTime Completes Public Offering Of Shares For USD 3.5 Million 36
BioTime Completes Private Placement Of Units For USD 9 Million 37
BioTime Accelerates Closing Date For Second Tranche Of Private Placement Of Shares For USD 3 Million 38
BioTime Announces Private Placement Of Common Stock 40
Acquisition 41
BioIVT Acquires Ascendance Biotech 41
BioTime Inc-Key Competitors 42
BioTime Inc-Key Employees 43
BioTime Inc-Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Joint Venture 45
Recent Developments 46
Financial Announcements 46
Aug 02, 2018: BioTime reports second quarter results and recent corporate accomplishments-2018 46
May 10, 2018: BioTime Reports First Quarter Results and Recent Corporate Accomplishments 48
Mar 15, 2018: BioTime Reports Fourth Quarter and Fiscal 2017 Results 50
Nov 09, 2017: BioTime Reports Third Quarter Results and Recent Corporate Accomplishments 52
Aug 02, 2017: BioTime Reports Second Quarter Results and Recent Accomplishments 54
May 10, 2017: BioTime Reports First Quarter Results and Recent Corporate Accomplishments 56
Mar 16, 2017: BioTime Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Recent Corporate Accomplishments 58
Feb 21, 2017: BioTime Reports Pro Forma Gain on Deconsolidation of OncoCyte Subsidiary 61
Corporate Communications 62
Sep 18, 2018: BioTime appoints Brian Culley as chief executive officer 62
Jun 05, 2018: AgeX Therapeutics Appoints John F. Mauldin to Board of Directors 63
Feb 26, 2018: BioTime Appoints Gary S. Hogge As Sr. Vice President, Clinical and Medical Affairs 64
Feb 22, 2018: BioTime Names Cavan Redmond As Board Director 65
Jul 13, 2017: BioTime Subsidiary AgeX Therapeutics Appoints Aubrey de Grey, Ph.D. as VP of New Technology Discovery 66
Feb 07, 2017: BioTime Appoints Industry Veteran, Stephana Patton, Ph.D., J.D., as General Counsel 67
Product News 68
Aug 16, 2018: BioTime to present data at the Military Health System Research Symposium 68
May 11, 2017: BioTime Presents Retinal Restoration Data at ARVO 69
Other Significant Developments 70
Jan 22, 2018: BioTime Announces 2018 Clinical and Corporate Milestone Targets 70
Appendix 71
Methodology 71
About GlobalData 71
Contact Us 71
Disclaimer 71
List of Figure
List of Figures
BioTime Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
BioTime Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
BioTime Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
BioTime Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
BioTime Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
BioTime Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
BioTime Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
BioTime Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 9
List of Table
List of Tables
BioTime Inc, Medical Equipment, Key Facts, 2017 2
BioTime Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
BioTime Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
BioTime Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
BioTime Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
BioTime Inc, Deals By Market, 2012 to YTD 2018 9
BioTime Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
OncoCyte Enters into Licensing Agreement with Cornell University for PanC-Dx 12
OncoCyte Enters into Co-Development Agreement with Abcodia for PanC-Dx Test 13
OncoCyte Expands Co-Development Agreement with Wistar Institute 14
Heraeus Medical Enters into Licensing Agreement with OrthoCyte 15
OncoCyte Enters into Licensing Agreement with Wistar Institute of Anatomy and Biology 16
OncoCyte to Raise USD4 Million in Private Placement of Shares and Warrants 18
OncoCyte Raises USD10 Million in Private Placement of Shares 19
BioTime Completes Public Offering of Shares for USD28.8 Million 20
OncoCyte Plans to Raise up to USD50 Million in Public Offering of Securities 22
OncoCyte Raises USD5.7 Million in Private Placement of Shares upon Exercise of Warrants 23
Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 24
BioTime to Raise up to USD25 Million in Private Placement of Shares 26
OncoCyte Raises USD2 Million in Private Placement of Shares upon Exercise of Warrants 27
OncoCyte Raises USD3.2 Million in Private Placement of Units 28
OncoCyte Raises USD7.3 Million in Private Placement of Units 29
BioTime Raises USD5 Million in Private Placement of Shares 30
BioTime Raises USD20.4 Million in Private Placement of Shares 31
OncoCyte Raises USD3.3 Million in Private Placement of Shares 33
BioTime Completes Private Placement Of Shares For USD 6.4 Million 34
BioTime Announces Public Offering Of Shares For Up To USD 15 Million 35
BioTime Completes Public Offering Of Shares For USD 3.5 Million 36
BioTime Completes Private Placement Of Units For USD 9 Million 37
BioTime Accelerates Closing Date For Second Tranche Of Private Placement Of Shares For USD 3 Million 38
BioTime Announces Private Placement Of Common Stock 40
BioIVT Acquires Ascendance Biotech 41
BioTime Inc, Key Competitors 42
BioTime Inc, Key Employees 43
BioTime Inc, Subsidiaries 44
BioTime Inc, Joint Venture 45
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.